Loading organizations...
Proteon Pharmaceuticals has raised $25.0M across 1 funding round.
Key people at Proteon Pharmaceuticals.
Proteon Pharmaceuticals has raised $25.0M in total across 1 funding round.
Proteon Pharmaceuticals develops bacteriophage-based feed additives that modulate the microbiome to improve animal and human health. Its core products target livestock and aquaculture, enabling farmers to reduce antibiotic use. Their technical approach leverages precision biology and proprietary phage-platform technology for sustainable bacterial disease management.
Founded in 2005 by Professor Jarosław Dastych, PhD, the Chief Executive Officer, Proteon Pharmaceuticals emerged from his deep research in immunology, toxicology, and molecular biology. His key insight was the significant potential of bacteriophages to offer sustainable solutions for managing bacterial infections in animal farming and aquaculture.
The company's solutions primarily serve livestock and aquaculture farmers aiming for improved productivity and sustainable protein production. Proteon Pharmaceuticals’ mission is to enhance animal and human health, increase environmental sustainability, and eliminate unnecessary antibiotic use, advancing economically efficient agricultural practices globally.
Key people at Proteon Pharmaceuticals.
Proteon Pharmaceuticals has raised $25.0M across 1 funding round. Most recently, it raised $25.0M Series U in August 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2021 | $25M Series U | — | Aqua Spark, Breakthrough Energy Ventures, Chalmers Ventures, Connolley, Future Shape, Graph Ventures, Seventure Partners, Alan Macintosh, Bradley Horowitz | Announced |
Proteon Pharmaceuticals has raised $25.0M in total across 1 funding round.
Proteon Pharmaceuticals's investors include Aqua Spark, Breakthrough Energy Ventures, Chalmers Ventures, Connolley, Future Shape, Graph Ventures, Seventure Partners, Alan MacIntosh, Bradley Horowitz.
Proteon Pharmaceuticals is a biotechnology company specializing in bacteriophage-based solutions for livestock and aquaculture, developing feed additives that modulate the microbiome to improve gut health, prevent bacterial infections, and reduce antibiotic use.[1][2][3][4] It serves farmers in poultry, aquaculture, and dairy sectors, addressing challenges like antimicrobial resistance (AMR), disease-related mortality, and unsustainable protein production by offering natural, eco-friendly products that enhance animal productivity and food safety.[3][4][5] Founded in 2005 and based in Łódź, Poland, the company has raised $31.99M in funding, reached Series B stage, and commercialized three products with five more in development, positioning it as a leader in sustainable agrotech.[1][3][6]
Proteon Pharmaceuticals was founded in 2005 by Prof. Jarosław Dastych, PhD, who serves as CEO and Board President, channeling his passion for bacteriophages—viruses known for over a century but overshadowed by antibiotics—into a dedicated biotech venture.[1][3][6] Dastych's expertise in molecular biology drove the creation of a proprietary bacteriophage platform technology, leveraging advances in genomics, AI, and scalable production to develop targeted phage cocktails for animal health.[1][3] Early traction came from recognizing bacteriophages' potential amid rising AMR concerns, leading to international awards and the commercialization of initial feed additives for livestock and aquaculture, with pivotal expansion including a Center for Bacteriophage Biotechnology opened in 2023.[3][6]
Proteon rides the wave of bacteriophage revival amid the global AMR crisis and demand for sustainable agriculture, where antibiotics' overuse threatens livestock productivity and food security.[1][3][6] Timing is ideal with molecular biology and AI enabling precise phage engineering, filling gaps left by antibiotics' decline and supporting EU/UN sustainability mandates for reduced chemical use in protein production.[2][4][5] Market forces like rising protein demand, regulatory pressures on antibiotics, and investor interest in agrobiotech (e.g., $32M raised) favor its growth, influencing the ecosystem by pioneering phage commercialization, inspiring competitors like Phagelux AgriHealth, and promoting microbiome-focused farming for healthier animals and safer food chains.[1][6]
Proteon is poised to expand its pipeline with five new phage solutions targeting broader bacterial threats in in-feed formats, scaling globally via its new biotech center, and potentially entering human health applications.[3][6] Trends like AI-driven biotech, stricter AMR regulations, and sustainable protein demands will accelerate adoption, evolving its influence from niche leader to paradigm-shifter in responsible farming. As antibiotic alternatives gain traction, Proteon's platform positions it to drive a healthier, greener future for global livestock and aquaculture, fulfilling its founding vision of precision biology for microbiome modulation.[3][6]
